Structure-guided identification and experimental validation of NAT10-targeting small molecules in colorectal cancer cells
Journal of Computer-Aided Molecular Design · 2026
DOI: 10.1007/s10822-026-00890-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Computer-Aided Molecular Design, 2026. Verfasst von Chao Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Proctology, Danyang TCM Hospital, Danyang, 212300, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Agents, Acetyltransferases, Small Molecule Libraries. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Colorectal cancer (CRC) remains a major cause of cancer-related mortality worldwide, and patients with advanced or metastatic disease still require more effective targeted therapeutic options. N-acetyltransferase 10 (NAT10), an RNA acetyltransferase responsible for N4-acetylcytidine (ac4C) modification, has been implicated in CRC progression, metastasis, immune evasion, and therapy resistance. The recently resolved human NAT10 structure (PDB ID: 9J3C) provides a structural basis for rational discovery of NAT10-directed chemical scaffolds. We combined large-scale virtual screening, molecular simulation, and cellular testing to identify NAT10-targeting compounds. Approximately 300,000 molecules were screened by hierarchical docking, followed by ADMET prediction, 100-ns molecular dynamics simulations, and MM/PBSA analysis. G856-6814 showed a predicted binding free energy of - 26.33 ± 3.37 kcal/mol and inhibited HCT116 cell viability with an IC50 of 211.6 ± 14.8 nM. In a recombinant enzyme assay, G856-6814 inhibited NAT10 acetyltransferase activity with an IC50 of 2.3 ± 0.4 µM. G856-6814 treatment increased the apparent NAT10 melting temperature from 50.4 ± 0.5 to 56.0 ± 0.8 °C. Treatment also reduced global RNA ac4C and ac4C enrichment on c-MYC, CCNA2, and CCNB1 transcripts. G856-6814 was 19.6-fold less potent against TIP60 and more than 43-fold less potent against p300 and GCN5. Together with the attenuation of cellular effects after NAT10 knockdown, these findings support G856-6814 as a NAT10-targeting inhibitory scaffold that requires broader selectivity and in vivo evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Proctology, Danyang TCM Hospital, Danyang, 212300, China.
- College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 211198, China.
- Department of Spleen and Stomach, Danyang TCM Hospital, Danyang, 212300, China.
- Department of Colorectal Medicine, Jiangsu Provincial Hospital of TCM, Nanjing, 210001, China.
- Department of Colorectal Surgery, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 215009, China. 472044066@qq.com.
- Department of Preventive Medicine, Jiangsu Provincial TCM Hospital, Nanjing, 210001, China. 13601401869@163.com.
Zitieren
APA
Xu, C., Zhao, S., Xu, B., Xu, J., Wu, Y., Zhang, D., Wu, B., & Zhou, Q. (2026). Structure-guided identification and experimental validation of NAT10-targeting small molecules in colorectal cancer cells. Journal of Computer-Aided Molecular Design. https://doi.org/10.1007/s10822-026-00890-7
Vancouver
Xu C, Zhao S, Xu B, Xu J, Wu Y, Zhang D, et al. Structure-guided identification and experimental validation of NAT10-targeting small molecules in colorectal cancer cells. Journal of Computer-Aided Molecular Design. 2026. doi:10.1007/s10822-026-00890-7
BibTeX
@article{Xu2026,
author = {Xu, Chao and Zhao, Shilei and Xu, Bing and Xu, Jiaping and Wu, Yongli and Zhang, Dan and Wu, Bensheng and Zhou, Qing},
title = {Structure-guided identification and experimental validation of NAT10-targeting small molecules in colorectal cancer cells},
journal = {Journal of Computer-Aided Molecular Design},
year = {2026},
doi = {10.1007/s10822-026-00890-7}
}
EUVIMED